Literature DB >> 30072003

Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.

Avirup Guha, Mohamed H Derbala, Qiuhong Zhao, Tracy E Wiczer, Jennifer A Woyach, John C Byrd, Farrukh T Awan, Daniel Addison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30072003      PMCID： PMC7529121          DOI： 10.1016/j.jacc.2018.06.002

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  4 in total

1.  Ventricular arrhythmias and sudden death in patients taking ibrutinib.

Authors:  Benjamin L Lampson; Lijian Yu; Robert J Glynn; Jacqueline C Barrientos; Eric D Jacobsen; Versha Banerji; Jeffrey A Jones; Renata Walewska; Kerry J Savage; Gregory F Michaud; Javid J Moslehi; Jennifer R Brown
Journal:  Blood       Date:  2017-02-21       Impact factor: 22.113

2.  Incidence of Idiopathic Ventricular Arrhythmias: A Population-Based Study.

Authors:  Surksha Sirichand; Ammar M Killu; Deepak Padmanabhan; David O Hodge; Alanna M Chamberlain; Peter A Brady; Suraj Kapa; Peter A Noseworthy; Douglas L Packer; Thomas M Munger; Bernard J Gersh; Christopher J McLeod; Win-Kuang Shen; Yong-Mei Cha; Samuel J Asirvatham; Paul A Friedman; Siva K Mulpuru
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-02

3.  Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Authors:  Tracy E Wiczer; Lauren B Levine; Jessica Brumbaugh; Jessica Coggins; Qiuhong Zhao; Amy S Ruppert; Kerry Rogers; Anli McCoy; Luay Mousa; Avirup Guha; Nyla A Heerema; Kami Maddocks; Beth Christian; Leslie A Andritsos; Samantha Jaglowski; Steven Devine; Robert Baiocchi; Jennifer Woyach; Jeffrey Jones; Michael Grever; Kristie A Blum; John C Byrd; Farrukh T Awan
Journal:  Blood Adv       Date:  2017-09-08

4.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
  4 in total
  29 in total

Review 1.  Bruton Tyrosine Kinase Inhibitors: Present and Future.

Authors:  Jan A Burger
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

Review 3.  Electrophysiologic Complications in Cancer Patients.

Authors:  Dae Hyun Lee; Sanjay Chandrashekhar; Michael G Fradley
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

Review 4.  Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.

Authors:  Fabienne Lucas; Jennifer A Woyach
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

Review 5.  Targeting BTK in CLL: Beyond Ibrutinib.

Authors:  David A Bond; Jennifer A Woyach
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

6.  Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies.

Authors:  Janice M Bonsu; Avirup Guha; Lawrence Charles; Vedat O Yildiz; Lai Wei; Brandee Baker; Jonathan E Brammer; Farrukh Awan; Maryam Lustberg; Raquel Reinbolt; Eric D Miller; Hani Jneid; Patrick Ruz; Rebecca R Carter; Michael W Milks; Electra D Paskett; Daniel Addison
Journal:  J Am Coll Cardiol       Date:  2020-02-18       Impact factor: 24.094

Review 7.  Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.

Authors:  Jennifer A Woyach
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 8.  Managing toxicities of Bruton tyrosine kinase inhibitors.

Authors:  Andrew Lipsky; Nicole Lamanna
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

9.  Hypertension and incident cardiovascular events following ibrutinib initiation.

Authors:  Tyler Dickerson; Tracy Wiczer; Allyson Waller; Jennifer Philippon; Kyle Porter; Devin Haddad; Avirup Guha; Kerry A Rogers; Seema Bhat; John C Byrd; Jennifer A Woyach; Farrukh Awan; Daniel Addison
Journal:  Blood       Date:  2019-11-28       Impact factor: 22.113

Review 10.  Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.

Authors:  Jennifer A Woyach
Journal:  Blood       Date:  2019-11-21       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.